Characterising the myocardial interstitial space: The clinical relevance of non-invasive imaging

Heart

Volumn 98, Issue 10, 2012, Pages 773-779

  White, Steven K ^a,b   Sado, Daniel M ^a,b   Flett, Andrew S ^a,b   Moon, James C ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMMONIA N 13; COLLAGEN; FUROSEMIDE; GADOLINIUM; LISINOPRIL; LOSARTAN;

AORTA STENOSIS; AORTA VALVE REPLACEMENT; CARDIOVASCULAR MAGNETIC RESONANCE; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; HEART AFTERLOAD; HEART AMYLOIDOSIS; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INTERSTITIUM; MOLECULAR IMAGING; MYOCARDIAL INTERSTITIAL SPACE; MYOCARDITIS; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84860915148     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2011-301515     Document Type: Review

References (83)

1. Bashey RI, Martinez-Hernandez A, Jimenez SA. Isolation, characterization, and localization of cardiac collagen type VI. Associations with other extracellular matrix components. Circ Res 1992;70:1006-17.
2. Manasek FJ. Macromolecules of the extracellular compartment of embryonic and mature hearts. Circ Res 1976;38:331-7.
3. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998;16:1031-41. (Pubitemid 28367959)
4. Weber KT. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989;13:1637-52. (Pubitemid 19145564)
5. Souders CA, Bowers SL, Baudino TA. Cardiac fibroblast: the renaissance cell. Circ Res 2009;105:1164-76.
6. Banerjee I, Fuseler JW, Price RL, et al. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007;293:H1883-91. (Pubitemid 47367239)
7. Baum J, Duffy HS. Fibroblasts and myofibroblasts: what are we talking about? J Cardiovasc Pharmacol 2011;57:376-9.
8. Baudino TA, Carver W, Giles W, et al. Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol 2006;291:H1015-26. (Pubitemid 44343642)
9. Rohr S. Cardiac fibroblasts in cell culture systems: myofibroblasts all along? J Cardiovasc Pharmacol 2011;57:389-99.
10. Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 2005;65:40-51. (Pubitemid 40038477)
11. Ahmed SH, Lindsey ML. Titin phosphorylation: myocardial passive stiffness regulated by the intracellular giant. Circ Res 2009;105:611-13.
12. Hudson B, Hidalgo C, Saripalli C, et al. Hyperphosphorylation of mouse cardiac titin contributes to transverse aortic constriction-induced diastolic dysfunction. Circ Res 2011;109:858-66.
13. Querejeta R, Lopez B, Gonzalez A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004;110:1263-8. (Pubitemid 39202343)
14. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:2260-4. (Pubitemid 38757595)
15. de Jong S, van Veen TA, van Rijen HV, et al. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 2011;57:630-8.
16. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-342. (Pubitemid 350041472)
17. Lopez B, Gonzalez A, Hermida N, et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010;299: H1-9.
18. McCurdy S, Baicu CF, Heymans S, et al. Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol 2010;48:544-9.
19. Bereczki E, Santha M. The role of biglycan in the heart. Connect Tissue Res 2008;49:129-32.
20. Polyakova V, Hein S, Kostin S, et al. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004;44:1609-18. (Pubitemid 39369793)
21. Benito B, Gay-Jordi G, Serrano-Mollar A, et al. Cardiac arrhythmogenic remodeling in a rat model of long-term intensive exercise training. Circulation 2011;123:13-22.
22. Krayenbuehl HP, Hess OM, Monrad ES, et al. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989;79:744-55. (Pubitemid 19100533)
23. Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circ J 2010;74:809-17.
24. Hudson MP, Armstrong PW, Ruzyllo W, et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006;48:15-20. (Pubitemid 43929218)
25. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov 2007;6:127-39. (Pubitemid 46758752)
26. Sado DM, Flett AS, Moon JC. Novel imaging techniques for diffuse myocardial fibrosis. Future Cardiol 2011;7:643-50.
27. Shan K, Bick RJ, Poindexter BJ, et al. Relation of tissue doppler derived myocardial velocities to myocardial structure and beta-adrenergic receptor density in humans. J Am Coll Cardiol 2000;36:891-6.
28. Kasner M, Westermann D, Lopez B, et al. Diastolic tissue doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol 2011;57:977-85.
29. Marwick TH, Schwaiger M. The future of cardiovascular imaging in the diagnosis and management of heart failure, part 1: tasks and tools. Circ Cardiovasc Imaging 2008;1:58-69.
30. Di Bello V, Giorgi D, Viacava P, et al. Severe aortic stenosis and myocardial function: diagnostic and prognostic usefulness of ultrasonic integrated backscatter analysis. Circulation 2004;110:849-55. (Pubitemid 39096014)
31. Mizuno R, Fujimoto S, Saito Y, et al. Non-invasive quantitation of myocardial fibrosis using combined tissue harmonic imaging and integrated backscatter analysis in dilated cardiomyopathy. Cardiology 2007;108:11-17. (Pubitemid 47014345)
32. Lythall DA, Bishop J, Greenbaum RA, et al. Relationship between myocardial collagen and echo amplitude in non-fibrotic hearts. Eur Heart J 1993;14:344-50. (Pubitemid 23103416)
33. Losi MA, Betocchi S, Chinali M, et al. Myocardial texture in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2007;20:1253-9. (Pubitemid 350026742)
34. Losi MA, Memoli B, Contaldi C, et al. Myocardial fibrosis and diastolic dysfunction in patients on chronic haemodialysis. Nephrol Dial Transpl 2010;25:1950-4.
35. Maceira AM, Barba J, Varo N, et al. Ultrasonic backscatter and serum marker of cardiac fibrosis in hypertensives. Hypertension 2002;39:923-8. (Pubitemid 34437551)
36. Di Bello V, Cucco C, Giannini C, et al. Myocardial tissue characterization and aortic stenosis. J Am Soc Echocardiogr 2010;23:1067-70.
37. Messroghli DR, Walters K, Plein S, et al. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med 2007;58:34-40. (Pubitemid 47229915)
38. Piechnik SK, Ferreira VM, Dall'Armellina E, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson 2010;12:69.
39. Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol 2008;52:1574-80.
40. Jellis C, Wright J, Kennedy D, et al. Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy. Circ Cardiovasc Imaging 2011.
41. Sueyoshi E, Sakamoto I, Uetani M. Contrast-enhanced myocardial inversion time at the null point for detection of left ventricular myocardial fibrosis in patients with dilated and hypertrophic cardiomyopathy: a pilot study. AJR Am J Roentgenol 2010;194:W293-8.
42. Arheden H, Saeed M, Higgins CB, et al. Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: comparison with 99mTc-DTPA autoradiography in rats. Radiology 1999;211:698-708. (Pubitemid 29249466)
43. Flacke SJ, Fischer SE, Lorenz CH. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Radiology 2001;218:703-10. (Pubitemid 32172551)
44. Klein C, Nekolla SG, Balbach T, et al. The influence of myocardial blood flow and volume of distribution on late Gd-DTPA kinetics in ischemic heart failure. J Magn Reson Imaging 2004;20:588-93.
45. Schelbert EB, Testa SM, Meier CG, et al. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson 2011;13:16.
46. Ugander M, Oki AJ, Hsu LY, et al. Extracellular volume imaging by magnetic resonance imaging provides insights into overt and sub-clinical myocardial pathology. Eur Heart J Published Online First: 24 January 2012: doi:10.1093/eurheartj/ehr481 2012.
47. Jerosch-Herold M, Sheridan DC, Kushner JD, et al. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2008;295:H1234-42.
48. Flett AS, Hayward MP, Ashworth MT, et al. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation 2010;122:138-44.
49. Messroghli DR, Radjenovic A, Kozerke S, et al. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med 2004;52:141-6. (Pubitemid 39295266)
50. Verhaert D, Thavendiranathan P, Giri S, et al. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc Imaging 2011;4(3):269-78.
51. Ferreira VM, Piechnik SK, Dall'Armellina E, et al. Quantification of acute myocardial injury by ShMOLLI T1-Mapping, T2-weighted and late gadolinium imaging in patients presenting with chest pain, positive troponins and non-obstructive coronary arteries [abstract]. J Cardiovasc Magn Reson 2011;13:P16.
52. Ugander M, Bagi PS, Oki AJ, et al. Quantitative T1-maps delineate myocardium at risk as accurately as T2-maps - experimental validation with microspheres [abstract]. J Cardiovasc Magn Reson 2011;13:O62.
53. White SK, Piechnik SK, Neubauer S, et al. Histological validation of ShMOLLI equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis [abstract]. J Cardiovasc Magn Reson 2012;14:O111.
54. Knaapen P, Gotte MJ, Paulus WJ, et al. Does myocardial fibrosis hinder contractile function and perfusion in idiopathic dilated cardiomyopathy? PET and MR imaging study. Radiology 2006;240:380-8. (Pubitemid 44098633)
55. Knaapen P, van Dockum WG, Bondarenko O, et al. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. J Nucl Med 2005;46:923-9. (Pubitemid 43733505)
56. Nahrendorf M, Sosnovik DE, French BA, et al. Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc imaging 2009;2:56-70.
57. Makowski MR, Ebersberger U, Nekolla S, et al. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J 2008;29:2201.
58. Sinusas AJ, Thomas JD, Mills G. The future of molecular imaging. JACC Cardiovasc Imaging 2011;4:799-806.
59. Sahul ZH, Mukherjee R, Song J, et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging 2011;4:381-91.
60. van den Borne SW, Isobe S, Zandbergen HR, et al. Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling. JACC Cardiovasc Imaging 2009;2:187-98.
61. Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-63.
62. Azevedo CF, Nigri M, Higuchi ML, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 2010;56:278-87.
63. Weidemann F, Herrmann S, Stork S, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009;120:577-84.
64. Fijalkowski M, Koprowski A, Galaska R, et al. Improvement of ultrasonic myocardial properties after aortic valve replacement for pure severe aortic stenosis: the predictive value of ultrasonic tissue characterization for left ventricle reverse remodeling. J Am Soc Echocardiogr 2010;23:1060-6.
65. Flett AS, Sado DM, Quarta G, et al. Beyond late gadolinium enhancement: the key role of diffuse myocardial fibrosis in severe aortic stenosis - an equilibrium contrast CMR study [abstract]. J Cardiovasc Magn Reson 2011;13:O39.
66. Picano E, Pelosi G, Marzilli M, et al. In vivo quantitative ultrasonic evaluation of myocardial fibrosis in humans. Circulation 1990;81:58-64. (Pubitemid 20031767)
67. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010;121:1645-54.
68. Diez J, Gonzalez A, Lopez B, et al. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat Clin Pract Cardiovasc Med 2005;2:209-16. (Pubitemid 40812484)
69. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
70. Lopez B, Querejeta R, Varo N, et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-91. (Pubitemid 32666949)
71. Lopez B, Querejeta R, Gonzalez A, et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009;53:236-42.
72. Sado DM, Flett AS, Cook CM, et al. The quantification and role of diffuse myocardial fibrosis in familial dilated cardiomyopathy - an equilibrium contrast cmr study [abstract]. J Cardiovasc Magn Reson 2011;13:O108.
73. Kwong RY, Sattar H, Wu H, et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 2008;118:1011-20.
74. Fang ZY, Yuda S, Anderson V, et al. Echocardiographic detection of early diabetic myocardial disease. J Am Coll Cardiol 2003;41:611-17. (Pubitemid 36223327)
75. Hosch W, Bock M, Libicher M, et al. MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol 2007;42:636-42. (Pubitemid 47262932)
76. Austin BA, Tang WH, Rodriguez ER, et al. Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2009;2:1369-77.
77. Sado DM, Flett AS, Hasleton J, et al. Myocardial interstitial expansion in health and disease - preliminary results from equilibrium contrast cardiovascular magnetic resonance (EQ-CMR) [abstract]. Eur Heart J 2011;32(Suppl 1):952.
78. Babu-Narayan SV, Uebing A, Davlouros PA, et al. Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot). Int J Cardiol 2012;154:299-305.
79. Babu-Narayan SV, Goktekin O, Moon JC, et al. Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation 2005;111:2091-8. (Pubitemid 40577904)
80. Broberg CS, Chugh SS, Conklin C, et al. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Circ Cardiovasc Imaging 2010;3:727-34.
81. Ugander M, Bagi PS, Booker JO, et al. Understanding why edema in salvaged myocardium is difficult to detect by late gadolinium enhancement [abstract]. J Cardiovasc Magn Reson 2012;14:O63.
82. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 2009;53:1475-87.
83. Monney PA, Sekhri N, Burchell T, et al. Acute myocarditis presenting as acute coronary syndrome: role of early cardiac magnetic resonance in its diagnosis. Heart 2011;97:1312-18